PMID- 35096057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2022
DP  - 2022
TI  - A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in 
      Triple-Negative Breast Cancer.
PG  - 2407211
LID - 10.1155/2022/2407211 [doi]
LID - 2407211
AB  - OBJECTIVE: To evaluate the efficacy and safety of programmed cell death 
      receptor-1 (PD-1)/programmed cell death-ligand protein-1 (PD-L1) inhibitors in 
      triple-negative breast cancer (TNBC) to provide a treatment basis for TNBC. 
      METHODS: Published case-control studies on PD-1/PD-L1 inhibitors in the treatment 
      of TNBC were retrieved from PubMed, Embase, and Cochrane Library databases, and 
      collected data were processed by RevMan 5.4. RESULTS: A total of 7 studies with 
      4340 study subjects were obtained, including 2092 PD-L1-negative cases, 1375 
      PD-L1-positive cases, and 847 PD-L1 unidentified cases. The use of PD-1/PD-L1 
      inhibitors showed no significant impact on patients' progression-free survival 
      (PFS) and overall survival (OS). The use of PD-1/PD-L1 inhibitors in the 
      PD-L1-positive subgroup significantly improved patients' PFS and OS. Treatment 
      with PD-1/PD-L1 inhibitors presented no significant effect on the incidence of 
      adverse events (AEs) but increased the risk of AE grade >/=3 and severe AEs (SAEs). 
      CONCLUSION: PD-1/PD-L1 inhibitors are effective in the treatment of TNBC, which 
      is strongly correlated with the expression of PD-L1; patient selection and 
      clinical application require further investigation and verification.
CI  - Copyright (c) 2022 Chaoyang Wang.
FAU - Wang, Chaoyang
AU  - Wang C
AUID- ORCID: 0000-0002-4721-6381
AD  - Department of Oncological Surgery, Hanzhong 3201 Hospital Affiliated to Xi'an 
      Jiaotong University, Hanzhong, China.
LA  - eng
PT  - Journal Article
DEP - 20220121
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC8799355
COIS- The author declares that there are no conflicts of interest.
EDAT- 2022/02/01 06:00
MHDA- 2022/02/01 06:01
PMCR- 2022/01/21
CRDT- 2022/01/31 05:57
PHST- 2021/11/25 00:00 [received]
PHST- 2021/12/20 00:00 [revised]
PHST- 2021/12/27 00:00 [accepted]
PHST- 2022/01/31 05:57 [entrez]
PHST- 2022/02/01 06:00 [pubmed]
PHST- 2022/02/01 06:01 [medline]
PHST- 2022/01/21 00:00 [pmc-release]
AID - 10.1155/2022/2407211 [doi]
PST - epublish
SO  - J Oncol. 2022 Jan 21;2022:2407211. doi: 10.1155/2022/2407211. eCollection 2022.